Unbilled STI-Screenings durch fehlende Krankenversicherungsdeckung
Definition
Comprehensive STI/HIV testing costs €200+ per screening in Germany. However, statutory health insurance (GKV) does NOT reimburse these costs for asymptomatic individuals unless they are HIV PrEP users or women under 25 seeking chlamydia testing. This creates a coverage gap where testing centers provide services but cannot bill, resulting in direct revenue loss or patient burden-shifting.
Key Findings
- Financial Impact: €200+ unbilled per asymptomatic screening; estimated €10-25M annual revenue leakage across German testing centers (CSHF, Checkpoint networks, 12 independent centers in Baden-Württemberg alone)
- Frequency: Per screening (every asymptomatic patient)
- Root Cause: German GKV insurance policy § SGB V excludes asymptomatic STI screening from coverage; testing centers required to provide service (public health mandate) but legally prevented from billing insurance
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Public Health.
Affected Stakeholders
Lab billing departments, Testing center accountants, Uninsured/low-income patients bearing cost
Deep Analysis (Premium)
Financial Impact
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Current Workarounds
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Get Solutions for This Problem
Full report with actionable solutions
- Solutions for this specific pain
- Solutions for all 15 industry pains
- Where to find first clients
- Pricing & launch costs
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Evidence Sources:
Related Business Risks
Zugangshürden durch Kostenbarrieren führen zu verlorenen Screenings
Manuelle Verwaltung von anonymisierten Patientendaten und Beratungsprozessen
Verwaltungsstau bei Notfallfördermittel-Vergabe (PPE-Innovationsfonds)
Fehlgeschlagene Maskenerzeugungskapazität: Subventionsverschwendung durch Marktmißtiming
Fehlende Konzeptentwicklung für Nationale Gesundheitsreserve: Strategische Lähmung durch unklare Verantwortlichkeiten
Mangelnde Koordination zwischen Ministerien: Verstoß gegen BHO und Kontrolltechnische Anforderungen
Request Deep Analysis
🇩🇪 Be first to access this market's intelligence